Afamelanotide + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Polymorphic Light Eruption

Conditions

Polymorphic Light Eruption

Trial Timeline

May 5, 2010 → —

NCT ID

NCT04704713

About Afamelanotide + Placebo

Afamelanotide + Placebo is a phase 3 stage product being developed by Clinuvel Pharmaceuticals for Polymorphic Light Eruption. The current trial status is completed. This product is registered under clinical trial identifier NCT04704713. Target conditions include Polymorphic Light Eruption.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04525157	Phase 2	Completed	Jun 6, 2014	Jun 6, 2016	Vitiligo
NCT01605136	Phase 3	Completed	May 1, 2012	Jul 1, 2013	Erythropoietic Protoporphyria
NCT04704713	Phase 3	Completed	May 5, 2010	—	Polymorphic Light Eruption
NCT01097044	Phase 2	Completed	Apr 1, 2010	Apr 1, 2011	Erythropoietic Protoporphyria
NCT00979745	Phase 3	Completed	Sep 1, 2009	May 1, 2011	Erythropoietic Protoporphyria
NCT04425746	Phase 2	Completed	Aug 5, 2008	May 28, 2009	Patients Undergoing Photodynamic Therapy Using Porfimer Sodium
NCT04053270	Phase 3	Completed	May 1, 2007	Dec 9, 2009	Erythropoietic Protoporphyria

Competing Products

2 competing products in Polymorphic Light Eruption

See all competitors

Product	Company	Stage	Hype Score
SGT-501	Solid Biosciences	Phase 1	30
Afamelanotide (CUV1647)	Clinuvel Pharmaceuticals	Pre-clinical	20